Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | CCR6 | P51684 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562932 | 0.86 | SIGMAR1 (0.58) | KMT2APOLBDRD4L3MBTL1HTT | |
| SCHEMBL17599750 | 0.84 | MEN1 (0.51) | KMT2AMEN1POLBDRD4L3MBTL1 | |
| SCHEMBL1274938 | 0.84 | HTT (0.73) | KMT2AMEN1DRD4L3MBTL1GAA | |
| SCHEMBL3482338 | 0.83 | SIGMAR1 (0.72) | DRD4HTR1ADRD2DRD3SIGMAR1 | |
| SCHEMBL9155290 | 0.82 | HTR1A (0.58) | KMT2ADRD4L3MBTL1HTTMAPK1 | |
| SCHEMBL10471813 | 0.81 | POLB (0.53) | KMT2AMEN1POLBDRD4L3MBTL1 | |
| SCHEMBL4628538 | 0.81 | GRM5 (0.56) | KMT2APOLBDRD4L3MBTL1HTT | |
| SCHEMBL27749320 | 0.81 | MC4R (0.70) | KMT2AMEN1POLBL3MBTL1GAA | |
| SCHEMBL11184187 | 0.80 | ALDH1A1 (0.66) | GAADRD2DRD3ALDH1A1MAPT | |
| SCHEMBL23536279 | 0.79 | HTR1A (0.58) | KMT2ADRD4L3MBTL1HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002421-A1 | PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | APICORE US LLC (US) | 2019-01-03 | — | — | US | claimed |
| US-20190002421-A1 | PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | APICORE US LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002421-A1 | PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | APICORE US LLC (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2017216805-A1 | INTERMEDIATES AND PROCESSES FOR PREPARATION OF VORTIOXETINE | LAKSHMI PRASAD ALAPARTHI (IN) | 2017-12-21 | — | — | WO | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| EP-1205473-A1 | VESAMICOL PIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-5885999-A | TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 1999-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | KMT2A 1330/4885MEN1 1339/4885POLB 2338/4885 |
| US-20190002421-A1 | PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CHRNA1, ADH1A, CHRNB1 | KMT2A 1685/4885MEN1 4389/4885POLB 570/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | KMT2A 1330/4885MEN1 1339/4885POLB 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.